Musk's Neuralink says second trial implant went well, no thread retraction issue
Neuralink logo and Elon Musk silhouette are seen in this illustration taken, December 19, 2022. REUTERS/Dado Ruvic/Illustration
(Reuters) - Elon Musk's brain technology startup Neuralink said its implant, designed to allow paralyzed patients to use digital devices by thinking alone, is working well in a second trial patient.
The company said the patient, identified as Alex, did not face issues of "thread retraction", unlike Noland Arbaugh, Neuralink's first patient who received the implant in January.
The tiny wires of the implant retracted post surgery for Arbaugh, resulting in a sharp reduction in the electrodes that could measure brain signals. The threads have stabilized for Arbaugh, Neuralink said.
Reuters had reported Neuralink was aware of this issue from its animal trials.
The company said on Wednesday it implemented measures such as reduction in the motion of the brain during surgery as well as limiting the gap between the implant and the surface of the brain to prevent similar issues in its second patient.
Neuralink is in the process of testing its device, which is intended to help people with spinal cord injuries. The device has allowed the first patient to play video games, browse the internet, post on social media and move a cursor on his laptop.
Last month, the company successfully implanted the device in the second patient, who has been using the device to play video games and learn how to design 3D objects.
(Reporting by Christy Santhosh in Bengaluru; Editing by Arun Koyyur)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Farage and Bardella's 'small boats' pact draws criticism in France
- Philippine VP Duterte posts bail after arrest order for alleged grave threats
- Chinese national rescued from Nepal tunnel 10 days after flash flood
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share